Equities Analysts Offer Predictions for Collegium Pharmaceutical Inc’s FY2019 Earnings (NASDAQ:COLL)

Collegium Pharmaceutical Inc (NASDAQ:COLL) – Research analysts at Gabelli cut their FY2019 EPS estimates for shares of Collegium Pharmaceutical in a note issued to investors on Wednesday, July 17th. Gabelli analyst K. Kedra now anticipates that the specialty pharmaceutical company will post earnings of ($0.30) per share for the year, down from their prior forecast of ($0.15). Gabelli also issued estimates for Collegium Pharmaceutical’s FY2020 earnings at $0.15 EPS, FY2021 earnings at $0.45 EPS, FY2022 earnings at $1.15 EPS and FY2023 earnings at $1.40 EPS.

A number of other equities research analysts have also weighed in on the stock. Janney Montgomery Scott began coverage on shares of PLx Pharma in a report on Friday, April 12th. They issued a “buy” rating for the company. BidaskClub lowered shares of Zebra Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, July 16th. ValuEngine lowered shares of Zosano Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. Cantor Fitzgerald set a $135.00 price objective on shares of Zimmer Biomet and gave the stock a “buy” rating in a report on Friday, April 26th. Finally, Zacks Investment Research downgraded shares of H&E Equipment Services from a “hold” rating to a “sell” rating in a research note on Wednesday. Three research analysts have rated the stock with a sell rating and five have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $26.17.



Shares of COLL opened at $10.35 on Friday. The company has a market cap of $351.56 million, a price-to-earnings ratio of -8.70 and a beta of 0.55. The company has a current ratio of 1.24, a quick ratio of 1.19 and a debt-to-equity ratio of 0.22. Collegium Pharmaceutical has a fifty-two week low of $10.18 and a fifty-two week high of $21.20. The business has a 50 day simple moving average of $12.03.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Wednesday, May 8th. The specialty pharmaceutical company reported ($0.29) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.30) by $0.01. The firm had revenue of $74.52 million during the quarter, compared to analyst estimates of $70.10 million. Collegium Pharmaceutical had a negative net margin of 10.36% and a negative return on equity of 30.87%.

A number of institutional investors have recently modified their holdings of the business. MERIAN GLOBAL INVESTORS UK Ltd purchased a new position in Collegium Pharmaceutical during the 1st quarter valued at $26,000. First Quadrant L P CA purchased a new position in Collegium Pharmaceutical during the 1st quarter valued at $36,000. DekaBank Deutsche Girozentrale increased its position in Collegium Pharmaceutical by 22.2% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 13,200 shares of the specialty pharmaceutical company’s stock valued at $221,000 after purchasing an additional 2,400 shares during the period. Sheaff Brock Investment Advisors LLC increased its position in Collegium Pharmaceutical by 14.9% during the 1st quarter. Sheaff Brock Investment Advisors LLC now owns 20,650 shares of the specialty pharmaceutical company’s stock valued at $313,000 after purchasing an additional 2,675 shares during the period. Finally, Bank of America Corp DE increased its position in Collegium Pharmaceutical by 17.2% during the 4th quarter. Bank of America Corp DE now owns 23,981 shares of the specialty pharmaceutical company’s stock valued at $412,000 after purchasing an additional 3,525 shares during the period. 94.83% of the stock is currently owned by institutional investors and hedge funds.

In related news, CEO Joseph Ciaffoni sold 5,851 shares of Collegium Pharmaceutical stock in a transaction on Friday, May 31st. The shares were sold at an average price of $11.52, for a total value of $67,403.52. Following the transaction, the chief executive officer now directly owns 190,755 shares of the company’s stock, valued at $2,197,497.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Michael Thomas Heffernan sold 25,000 shares of Collegium Pharmaceutical stock in a transaction on Monday, July 15th. The stock was sold at an average price of $11.26, for a total transaction of $281,500.00. Following the completion of the transaction, the director now directly owns 132,069 shares in the company, valued at $1,487,096.94. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 91,144 shares of company stock worth $1,075,506. 8.08% of the stock is owned by insiders.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.

Read More: Special Dividends

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.